Successful Marketing Applications for Regulatory Approval

Preparing Regulatory Marketing Applications to Their Successful Conclusions Is Our Focus

Veristat delivers integrated marketing application (NDA, BLA, MAA, NDS, jNDA, etc.) preparation expertise with a track record of success and achievement of seemingly impossible deadlines.  Our success lies in our ability to navigate operationally complex submissions, overcome data analysis challenges, and streamline the medical writing process with an integrated team focused on creativity, flexibility, and quality.

In 2021, Veristat teams supported marketing applications for 12% of all FDA Novel Drug Approvals. 

Learn more.

When the Final Milestone is Regulatory Approval 

We provide strategic consulting, biostatistical and programming support, CDISC compliant data standardization, and medical writing services to help you prepare and defend your regulatory submissions. We advise on the overall regulatory submission strategy and assist with developing the overall marketing application project plan and timelines.   We know how to work collaboratively with other third parties to bring all aspects of the submission timeline together. And, our regulatory publishing team is poised to submit your marketing applications to FDA.

Veristat is proud to have supported the preparation of 75 marketing applications that are now approved for patients. For these approved products, direct involvement included analysis and standardization of the clinical trial data, writing of the application’s modules, and/or publishing to the regulatory agencies.

View our approval record to see how we help sponsors bring life-changing therapies to patients everywhere.

Veristat_icon_data manager

To date, our scientific-minded teams have prepared

> 140 Marketing Applications


Veristat_icon_regulatory-approval-216-1


which have led to

> 75 Regulatory Approvals

from regulatory agencies around the world.



Navigating the Marketing Application Timeline, Preparation, and Publishing Process

MarketingAppOnlyChart_DarkGreenwithFade Background_Aug2021-1

Our teams are highly skilled and experienced in supporting the development of the following documents and analyses:

  • Phase III Pivotal Clinical Study Reports
  • Modules 2.3 and 2.4
  • Clinical Overview – Module 2.5
  • Summary of Clinical Efficacy (SCE) – Module 2.7.3
  • Summary of Clinical Safety (SCS) – Module 2.7.4
  • Module 3 Gap Analysis
  • Integrated Summary of Safety (ISS) – Module 5
  • Integrated Summary of Efficacy (ISE) – Module 5
  • Regulatory Analysis of Overall Application
  • SDTM Compliant Dataset
  • ADaM Compliant Datasets
  • ISS/ISE ADaM Dataset Creation
  • Regulatory Briefing documents
  • Written and Rapid Responses to Regulatory Authority Questions
  • Creation of Slides for Regulatory Presentations
  • 4-Month Safety Updates
  • Annual Reports

Our Expertise In Marketing Application Preparation

Regulatory CRO Experts at FDA Meeting Support

Veristat has been instrumental in the preparation of over 140 marketing applications that have led to 75 approvals so far. Our teams have represented pharmaceutical and biotechnology companies in direct regulatory interaction with the US FDA, Health Canada, European Medicines Agency (EMA), Korea FDA, and Japan FDA.  We have participated in on-site meetings at regulatory agencies and acted as statistical and clinical experts for advisory panel meetings, including acting as the client statistical representative for many of these panels.

Our senior consultants have over twenty-five years of experience guiding companies through the regulatory submission process. We bring together expert regulatory consultants, biostatisticians, medical writers, data standards professionals, and statistical programmers who work collaboratively to help our clients prepare their regulatory dossiers for submission and continue to support them throughout the agency review process.                                                     

Learn More with These Resources

Infographic

Why and When to Hold a Pre-IND Meeting with FDA

While a pre-IND Meeting with the FDA is optional, the Regulatory team at Veristat highly recommends that all
drug developers planning to submit an IND to the FDA have a ...

Download

Infographic

Similarities and Differences Between the CTA and IND

Suppose the goal of a development program is to initiate clinical trials within European member states, the United Kingdom, or North America. In
that case, strategic ...

Download

Case Study

First Gene Therapy Approved in Europe

Veristat was brought in to create and manage a full development program for a gene therapy for a very rare inherited disorder. The work involved charting the course in ...

Download
Request A Proposal